Pfizer announced it will discontinue the development of the twice-daily version of its experimental weight loss pill after phase 2 trials showed high rates of side effects in patients. Patients taking the twice-daily pill lost significant weight, but many struggled with side effects like nausea, vomiting, and diarrhea. Over 50% of patients stopped taking the pill due to side effects. This is a setback for Pfizer's hopes to enter the lucrative $90 billion weight loss drug market. Pfizer is behind competitors like Novo Nordisk and Eli Lilly in developing more convenient pill treatments for weight loss.
Category
đź—ž
NewsTranscript
00:00 It's Benzinga and here's what's on the block.
00:02 Pfizer announced that it will discontinue the development of the twice-daily version
00:06 of its experimental weight loss pill after the phase 2 trials showed high rates of side
00:10 effects in patients.
00:12 Patients taking the twice-daily pill lost significant weight, but many struggled with
00:15 side effects like nausea, vomiting, and diarrhea.
00:18 Over 50% of patients stopped taking the pill due to these side effects.
00:22 Now this is a setback for Pfizer's hopes to enter the lucrative $90 billion weight
00:26 loss drug market.
00:28 Pfizer is behind competitors like Novo Nordisk and Eli Lilly in developing more convenient
00:32 pill treatments for weight loss.
00:34 For all things money, visit Benzinga.com.
00:36 [MUSIC]